Deutsch English Français

Contact

EP1812433

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1812433

EP1812433 - IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 27.05.2016 Database last updated on 16.07.2024
Most recent event Tooltip	01.09.2017	Lapse of the patent in a contracting state New state(s): BG, CY	published on 04.10.2017 [2017/40]
Applicant(s)	For all designated states Cancer Research Technology Limited Angel Building 407 St. John Street London EC1V 4AD / GB
	For all designated states Institute of Cancer Research: Royal Cancer Hospital (The) 123 Old Brompton Road London Greater London SW7 3RP / GB
	For all designated states Astex Therapeutics Limited 436 Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0QA / GB
	[2015/38]
Former [2014/46]	For all designated states Cancer Research Technology Limited Angel Building 407 St. John Street London EC1V 4AD / GB
	For all designated states Institute of Cancer Research: Royal Cancer Hospital (The) 123 Old Brompton Road London Greater London SW7 3RP / GB
	For all designated states Astex Therapeutics Limited 436 Cambridge Science Park Milton Park Cambridge Cambridgeshire CB4 0QA / GB
Former [2011/28]	For all designated states Cancer Research Technology Limited Angel Building 407 St. John Street London EC1V 4AD / GB
	For all designated states The Institute of Cancer Research : The Royal Cancer Hospital 123 Old Brompton Road London Greater London SW7 3RP / GB
	For all designated states Astex Therapeutics Limited 436 Cambridge Science Park Milton Park Cambridge Cambridgeshire CB4 0QA / GB
Former [2007/31]	For all designated states Cancer Research Technology Limited Sardinia House, Sardinia Street London WC2A 3NL / GB
	For all designated states The Institute of Cancer Research : The Royal Cancer Hospital 123 Old Brompton Road London Greater London SW7 3RP / GB
	For all designated states Astex Therapeutics Limited 436 Cambridge Science Park Milton Park Cambridge Cambridgeshire CB4 0QA / GB
Inventor(s)	01 / NICULESCU-DUVAZ, Dan Cancer Research UK Center Institute of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	02 / Springer, Caroline Joy Cancer Research UK Center Institute of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	03 / Gill, Adrian Liam Astex Therapeutics Limited 436 Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0QA / GB
	04 / Taylor, Richard David Astex Therapeutics Limited 436 Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0QA / GB
	05 / Marais, Richard Malcolm The Institute of Cancer Research 237 Fulham Road London Greater London SW3 6JB / GB
	06 / DIJKSTRA, Harmen Duivenkamp 872 NL-3607 WH Maarssen / NL
	07 / Gaulon, Catherine Laboratoire de Synthese Organique UMR CNRS 6011 Universite du Maine F-72085 Le Mans Cedex 9 / FR
	08 / Menard, Delphine Cancer Research UK Centre Inst. of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	09 / Roman Vela, Esteban Cancer Research UK Centre Inst. of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	[2015/30]
Former [2007/31]	01 / NICULESCU-DUVAZ, Dan Cancer Research UK Center Institute of Cancer Research, 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	02 / Springer, Caroline Joy Cancer Research UK Center Institute of Cancer Research, 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	03 / Gill, Adrian Liam Astex Therapeutics Limited 436 Cambridge Science Park, Milton Road Cambridge Cambridgeshire CB4 0QA / GB
	04 / Taylor, Richard David Astex Therapeutics Limited 436 Cambridge Science Park, Milton Road Cambridge Cambridgeshire CB4 0QA / GB
	05 / Marais, Richard Malcolm The Institute of Cancer Research, 237 Fulham Road London Greater London SW3 6JB / GB
	06 / DIJKSTRA, Harmen Duivenkamp 872 NL-3607 WH Maarssen / NL
	07 / Gaulon, Catherine Laboratoire de Synthese Organique UMR CNRS 6011, Universite du Maine F-72085 Le Mans Cedex 9 / FR
	08 / Menard, Delphine Cancer Research UK Centre Inst. of Cancer Research, 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
	09 / Roman Vela, Esteban Cancer Research UK Centre Inst. of Cancer Research, 15 Cotswold Road Sutton, Surrey SM2 5NG / GB
Representative(s)	Wytenburg, Wilhelmus Johannes, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
	[2015/30]
Former [2007/31]	Wytenburg, Wilhelmus Johannes, et al Mewburn Ellis LLP York House 23 Kingsway London WC2B 6HP / GB
Application number, filing date	05796691.3	21.10.2005
	[2007/31]
	WO2005GB04081
Priority number, date	GB20040023554	22.10.2004 Original published format: GB 0423554
	US20040620658P	22.10.2004 Original published format: US 620658 P
	[2007/31]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2006043090
	Date:	27.04.2006
	Language:	EN
	[2006/17]
	Type:	A1 Application with search report
	No.:	EP1812433
	Date:	01.08.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 27.04.2006 takes the place of the publication of the European patent application.
	[2007/31]
	Type:	B1 Patent specification
	No.:	EP1812433
	Date:	22.07.2015
	Language:	EN
	[2015/30]
Search report(s)	International search report - published on:	EP	27.04.2006
Classification	IPC:	C07D471/04, C07D498/04, A61K31/4353, A61P35/00	[2007/31]
	CPC:	C07D471/04 (EP,NO,US); A61K31/437 (NO); A61P35/00 (EP); A61P43/00 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2015/30]
Former [2007/31]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
Extension states	AL	11.05.2007
	BA	11.05.2007
	HR	11.05.2007
	MK	11.05.2007
	YU	11.05.2007
Title	German:	IMIDAZO[4,5-B]PYRIDIN-2-ON- UND OXAZOLO[4,5-B]PYRIDIN-2-ON-VERBINDUNGEN UND ANALOGE DAVON ALS THERAPEUTISCHE VERBINDUNGEN	[2014/20]
	English:	IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS	[2007/31]
	French:	COMPOSES D' IMIDAZO[4,5-B]PYRIDIN-2-ONE ET OXAZOLO[4,5-B]PYRIDIN-2-ONE ET LEURS ANALOGUES UTILISES A DES FINS THERAPEUTIQUES	[2014/20]
	Former [2007/31]	IMIDAZO[4,5-B]PYRIDIN-2-ON- UNDOXAZOLO[4,5-B]PYRIDIN-2-ON-VERBINDUNGEN UND ANALOGE DAVON ALS THERAPEUTISCHEVERBINDUNGEN
	Former [2007/31]	COMPOSES D IMIDAZO[4,5-B]PYRIDIN-2-ONE ET OXAZOLO[4,5-B]PYRIDIN-2-ONE ET LEURS ANALOGUES UTILISES A DES FINS THERAPEUTIQUES
Entry into regional phase	11.05.2007	National basic fee paid
	11.05.2007	Designation fee(s) paid
	11.05.2007	Examination fee paid
Examination procedure	11.05.2007	Examination requested [2007/31]
	13.07.2007	Amendment by applicant (claims and/or description)
	23.07.2010	Despatch of a communication from the examining division (Time limit: M06)
	18.05.2011	Reply to a communication from the examining division
	25.04.2014	Communication of intention to grant the patent
	15.10.2014	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
	18.12.2014	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	04.02.2015	Communication of intention to grant the patent
	11.06.2015	Fee for grant paid
	11.06.2015	Fee for publishing/printing paid
	11.06.2015	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 23.07.2010
Opposition(s)	25.04.2016	No opposition filed within time limit [2016/26]
Request for further processing for:	The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
	18.12.2014	Request for further processing filed
	18.12.2014	Full payment received (date of receipt of payment) Request granted
	20.01.2015	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	18.05.2011	Request for further processing filed
	18.05.2011	Full payment received (date of receipt of payment) Request granted
	01.06.2011	Decision despatched
Fees paid	Renewal fee
	23.10.2007	Renewal fee patent year 03
	21.10.2008	Renewal fee patent year 04
	20.10.2009	Renewal fee patent year 05
	21.10.2010	Renewal fee patent year 06
	20.10.2011	Renewal fee patent year 07
	22.10.2012	Renewal fee patent year 08
	21.10.2013	Renewal fee patent year 09
	24.10.2014	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	22.07.2015
	BE	22.07.2015
	BG	22.07.2015
	CY	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	MC	22.07.2015
	RO	22.07.2015
	SI	22.07.2015
	SK	22.07.2015
	LU	21.10.2015
	IS	22.11.2015
	[2017/39]
Former [2017/03]	AT	22.07.2015
	BE	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	MC	22.07.2015
	RO	22.07.2015
	SI	22.07.2015
	SK	22.07.2015
	LU	21.10.2015
	IS	22.11.2015
Former [2016/36]	AT	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	MC	22.07.2015
	RO	22.07.2015
	SI	22.07.2015
	SK	22.07.2015
	LU	21.10.2015
	IS	22.11.2015
Former [2016/28]	AT	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	MC	22.07.2015
	RO	22.07.2015
	SK	22.07.2015
	LU	21.10.2015
	IS	22.11.2015
Former [2016/26]	AT	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	RO	22.07.2015
	SK	22.07.2015
	LU	21.10.2015
	IS	22.11.2015
Former [2016/23]	AT	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	RO	22.07.2015
	SK	22.07.2015
	IS	22.11.2015
Former [2016/22]	AT	22.07.2015
	EE	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	IS	22.11.2015
Former [2016/12]	AT	22.07.2015
	LT	22.07.2015
	LV	22.07.2015
	IS	22.11.2015
Former [2016/10]	LT	22.07.2015
	LV	22.07.2015
	IS	22.11.2015
Former [2016/09]	LT	22.07.2015
	LV	22.07.2015
Former [2016/07]	LT	22.07.2015
Cited in	International search	[A]US2004082583 (CHEUNG MUI [US], et al) [A] 1-100 * abstract * * example - * * claim - *;
		[A] - HAESSLEIN J ET AL, "RECENT ADVANCES IN CYCLIN-DEPENDENT KINASE INHIBITION. PURINE-BASED DERIVATIVES AS ANTI-CANCER AGENTS. ROLES AND PERSPECTIVES FOR THE FUTURE", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (2002), vol. 2, no. 9, ISSN 1568-0266, pages 1037 - 1050, XP009023064 [A] 1-100 * abstract * * page 1040; examples 5,14 * DOI: http://dx.doi.org/10.2174/1568026023393291
		[A] - ITAYA T ET AL, "Syntheses of the marine ascidian purine aplidiamine and its 9-beta-d-ribofuranoside", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, (19980625), vol. 39, no. 26, ISSN 0040-4039, pages 4695 - 4696, XP004130898 [A] 1,2,35 * page 4696; example 3b * DOI: http://dx.doi.org/10.1016/S0040-4039(98)00880-6
	by applicant	US2004082583
		- HAESSLEIN ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2002), vol. 2, no. 9, pages 1037 - 1050
		- ITAYA ET AL., TETRAHEDRON LETTERS, (1998), vol. 39, no. 26, pages 4695 - 4696
		- MARAIS R. ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 4378 - 4383
		- DAVIES, H. ET AL., NATURE, (2002), vol. 417, pages 949 - 954

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p